Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Mesalazine controlled release - Takeda

Next Previous
X
Search
Drug Profile

Mesalazine controlled release - Takeda

Alternative Names: Lialda; MD-0901; Mesalamine oral - Takeda; Mesalazine MMX™; Mesavance; Mesavancol; Mezavant; Mezavant XL; MMX Mesalamine; SPD 476

Latest Information Update: 30 Jul 2024

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Cosmo Pharmaceuticals
  • Developer Cosmo Pharmaceuticals; Mochida Pharmaceutical; Shire; Takeda
  • Class Aminosalicylic acids; Anti-inflammatories; Antineoplastics; Irritable bowel syndrome therapies; Small molecules
  • Mechanism of Action Lipoxygenase-cyclooxygenase inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Marketed Ulcerative colitis
  • No development reported Irritable bowel syndrome
  • Discontinued Diverticulitis

Most Recent Events

  • 22 Jul 2024 Preregistration for Ulcerative colitis (In Children) in Japan (PO)
  • 08 Mar 2022 No development reported - Phase-III for Irritable bowel syndrome in USA (PO)
  • 22 Apr 2019 Shire Human Genetic Therapies and University of Utah completes a phase III trial in Irritable bowel syndrome in USA (PO, Tablet) (NCT01412372)

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top